Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia

M. Hofmans, T. Lammens, B. Depreter, Y. Wu, M. Erlacher, A. Caye, H. Cavé, C. Flotho, V. de Haas, CM. Niemeyer, J. Stary, F. Van Nieuwerburgh, D. Deforce, W. Van Loocke, P. Van Vlierberghe, J. Philippé, B. De Moerloose

. 2021 ; 11 (1) : 2801. [pub] 20210202

Language English Country Great Britain

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004631

Juvenile myelomonocytic leukemia (JMML) treatment primarily relies on hematopoietic stem cell transplantation and results in long-term overall survival of 50-60%, demonstrating a need to develop novel treatments. Dysregulation of the non-coding RNA transcriptome has been demonstrated before in this rare and unique disorder of early childhood. In this study, we investigated the therapeutic potential of targeting overexpressed long non-coding RNAs (lncRNAs) in JMML. Total RNA sequencing of bone marrow and peripheral blood mononuclear cell preparations from 19 untreated JMML patients and three healthy children revealed 185 differentially expressed lncRNA genes (131 up- and 54 downregulated). LNA GapmeRs were designed for 10 overexpressed and validated lncRNAs. Molecular knockdown (≥ 70% compared to mock control) after 24 h of incubation was observed with two or more independent GapmeRs in 6 of them. For three lncRNAs (lnc-THADA-4, lnc-ACOT9-1 and NRIR) knockdown resulted in a significant decrease of cell viability after 72 h of incubation in primary cultures of JMML mononuclear cells, respectively. Importantly, the extent of cellular damage correlated with the expression level of the lncRNA of interest. In conclusion, we demonstrated in primary JMML cell cultures that knockdown of overexpressed lncRNAs such as lnc-THADA-4, lnc-ACOT9-1 and NRIR may be a feasible therapeutic strategy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004631
003      
CZ-PrNML
005      
20220127145113.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-021-82509-5 $2 doi
035    __
$a (PubMed)33531590
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hofmans, Mattias $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium. mattias.hofmans@ugent.be $u Department of Diagnostic Sciences, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium. mattias.hofmans@ugent.be
245    10
$a Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia / $c M. Hofmans, T. Lammens, B. Depreter, Y. Wu, M. Erlacher, A. Caye, H. Cavé, C. Flotho, V. de Haas, CM. Niemeyer, J. Stary, F. Van Nieuwerburgh, D. Deforce, W. Van Loocke, P. Van Vlierberghe, J. Philippé, B. De Moerloose
520    9_
$a Juvenile myelomonocytic leukemia (JMML) treatment primarily relies on hematopoietic stem cell transplantation and results in long-term overall survival of 50-60%, demonstrating a need to develop novel treatments. Dysregulation of the non-coding RNA transcriptome has been demonstrated before in this rare and unique disorder of early childhood. In this study, we investigated the therapeutic potential of targeting overexpressed long non-coding RNAs (lncRNAs) in JMML. Total RNA sequencing of bone marrow and peripheral blood mononuclear cell preparations from 19 untreated JMML patients and three healthy children revealed 185 differentially expressed lncRNA genes (131 up- and 54 downregulated). LNA GapmeRs were designed for 10 overexpressed and validated lncRNAs. Molecular knockdown (≥ 70% compared to mock control) after 24 h of incubation was observed with two or more independent GapmeRs in 6 of them. For three lncRNAs (lnc-THADA-4, lnc-ACOT9-1 and NRIR) knockdown resulted in a significant decrease of cell viability after 72 h of incubation in primary cultures of JMML mononuclear cells, respectively. Importantly, the extent of cellular damage correlated with the expression level of the lncRNA of interest. In conclusion, we demonstrated in primary JMML cell cultures that knockdown of overexpressed lncRNAs such as lnc-THADA-4, lnc-ACOT9-1 and NRIR may be a feasible therapeutic strategy.
650    _2
$a mladiství $7 D000293
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
650    _2
$a genový knockdown $7 D055785
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a juvenilní myelomonocytární leukemie $x krev $x farmakoterapie $x genetika $x patologie $7 D054429
650    _2
$a leukocyty mononukleární $7 D007963
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a primární buněčná kultura $7 D061251
650    _2
$a RNA dlouhá nekódující $x antagonisté a inhibitory $x genetika $x metabolismus $7 D062085
650    _2
$a sekvenování transkriptomu $7 D000081246
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lammens, Tim $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium $u Cancer Research Institute Ghent, Ghent University, Ghent, Belgium
700    1_
$a Depreter, Barbara $u Department of Laboratory Medicine Hematology, University Hospital Brussels, Brussels, Belgium
700    1_
$a Wu, Ying $u Faculty of Biology, University of Freiburg, Freiburg, Germany $u Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
700    1_
$a Erlacher, Miriam $u Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany $u German Cancer Consortium, Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany
700    1_
$a Caye, Aurélie $u Department of Genetics, University Hospital of Robert Debré (APHP) and INSERM U1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
700    1_
$a Cavé, Hélène $u Department of Genetics, University Hospital of Robert Debré (APHP) and INSERM U1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
700    1_
$a Flotho, Christian $u Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany $u German Cancer Consortium, Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany
700    1_
$a de Haas, Valerie $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Dutch Childhood Oncology Group, The Hague, The Netherlands
700    1_
$a Niemeyer, Charlotte M $u Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany $u German Cancer Consortium, Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany
700    1_
$a Stary, Jan $u Department of Pediatric Hematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Van Nieuwerburgh, Filip $u Laboratory for Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
700    1_
$a Deforce, Dieter $u Laboratory for Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
700    1_
$a Van Loocke, Wouter $u Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
700    1_
$a Van Vlierberghe, Pieter $u Cancer Research Institute Ghent, Ghent University, Ghent, Belgium $u Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
700    1_
$a Philippé, Jan $u Department of Diagnostic Sciences, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium $u Cancer Research Institute Ghent, Ghent University, Ghent, Belgium
700    1_
$a De Moerloose, Barbara $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium $u Cancer Research Institute Ghent, Ghent University, Ghent, Belgium
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 2801
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33531590 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145109 $b ABA008
999    __
$a ok $b bmc $g 1751940 $s 1155780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 1 $d 2801 $e 20210202 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220113
Back

Find record

Citation metrics

Archiving options